Piper Sandler Q1 Healthcare ECM Market Share Spikes; DCM Advisory Leads Non-M&A Growth
Piper Sandler closed several bank M&A deals in Q1 despite a slowdown in large transactions, while its derivative desk saw increased hedging activity during forward-rate volatility. The firm captured outsized Healthcare equity capital market share, cautioned that this level may not persist, and Debt Capital Markets advisory drove non-M&A growth.
1. Bank M&A and Hedging Activity
Piper Sandler reported a solid Q1 in bank M&A with several closings, although larger transactions have slowed from earlier expectations. Its derivative desk experienced heightened client demand and increased completed hedging transactions as forward-rate volatility spurred more active positioning.
2. Healthcare Equity Capital Markets Performance
The firm achieved an outsized share in Healthcare equity capital markets, buoyed by strong biotech trading and larger fee mandates in Q1. Management noted this exceptional market share is unlikely to be sustainable through Q2, even as the broader biotech issuance window remains open.
3. Advisory Outlook and Sector Variations
Advisory fees are expected to dip sequentially amid choppy macro conditions, with bank deal announcements down and Healthcare and MedTech deals from an exceptional Q1 set to be difficult to replicate. Sponsor-driven deal pitches remain robust, but the conversion to actual transactions is occurring at a cautious pace.
4. Non-M&A Business Strength
Debt Capital Markets advisory emerged as the standout non-M&A segment, delivering outsized Q1 performance over restructuring and private capital advisory. The firm’s recent private capital acquisition continues to contribute through continuation and other transactions, supporting its broader fee diversification strategy.